Manufacturer of Controlled Substances Notice of Application Cody Laboratories, Inc., 1890 [2014-00204]
Download as PDF
1890
Federal Register / Vol. 79, No. 7 / Friday, January 10, 2014 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
Drug
Schedule
2,5-Dimethoxyamphetamine
(7396).
JWH–398 (7398) ..........................
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
5-Methoxy-3,4methylenedioxyamphetamine
(7401).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
5-Methoxy-N-Ndimethyltryptamine (7431).
Alpha-methyltryptamine (7432) ....
Bufotenine (7433) .........................
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
N-Ethyl-1-phenylcyclohexylamine
(7455).
N-Benzylpiperazine (7493) ...........
2C–D (7508) .................................
2C–E (7509) .................................
2C–H (7517) .................................
2C–I (7518) ..................................
2C–C (7519) .................................
2C–N (7521) .................................
2C–P (7524) .................................
2C–T–4 (7532) .............................
MDPV (7535) ................................
Methylone (7540) .........................
AM–694 (7694) .............................
Desmorphine (9055) .....................
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Morphine-N-oxide (9307) .............
Normorphine (9313) .....................
Tilidine (9750) ...............................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Pentobarbital (2270) .....................
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Levomethorphan (9210) ...............
Meperidine (9230) ........................
Meperidine intermediate-B (9233)
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
VerDate Mar<15>2010
16:40 Jan 09, 2014
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Jkt 232001
The company plans to manufacture
reference standards for distribution to
their research and forensics customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic
tetrahydrocannabinol (7370). No other
activity for this drug code is authorized
for this registration.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than March 11, 2014.
Dated: December 31, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–00200 Filed 1–9–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Tapentadol (9780) ........................
Fentanyl (9801) ............................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
The company plans on manufacturing
the listed controlled substances in bulk
for sale to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than March 11, 2014.
Dated: December 31, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–00204 Filed 1–9–14; 8:45 am]
Drug Enforcement Administration
BILLING CODE 4410–09–P
Manufacturer of Controlled
Substances Notice of Application Cody
Laboratories, Inc.
DEPARTMENT OF JUSTICE
Pursuant to 21 CFR 1301.33(a), this is
notice that on June 12, 2013, Cody
Laboratories, Inc., 601 Yellowstone
Avenue, Cody, Wyoming 82414, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
4-Anilino-N-phenethyl-4-piperidine
(ANPP) (8333).
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Organix, Inc.
By Notice dated August 20, 2013, and
published in the Federal Register on
August 26, 2013, 78 FR 52801, Organix,
Inc., 240 Salem Street, Woburn,
Massachusetts 01801, made application
to the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Schedule
I
I
I
I
The company plans to synthesize
small quantities of the listed controlled
substances to make reference standards
which will be distributed to their
customers.
E:\FR\FM\10JAN1.SGM
10JAN1
Agencies
[Federal Register Volume 79, Number 7 (Friday, January 10, 2014)]
[Notices]
[Page 1890]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-00204]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances Notice of Application Cody
Laboratories, Inc.
Pursuant to 21 CFR 1301.33(a), this is notice that on June 12,
2013, Cody Laboratories, Inc., 601 Yellowstone Avenue, Cody, Wyoming
82414, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)..................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Amobarbital (2125)......................... II
Pentobarbital (2270)....................... II
Secobarbital (2315)........................ II
4-Anilino-N-phenethyl-4-piperidine (ANPP) II
(8333).
Phenylacetone (8501)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Diphenoxylate (9170)....................... II
Ecgonine (9180)............................ II
Hydrocodone (9193)......................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Oxymorphone (9652)......................... II
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Tapentadol (9780).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans on manufacturing the listed controlled substances
in bulk for sale to its customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODW), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than March 11, 2014.
Dated: December 31, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2014-00204 Filed 1-9-14; 8:45 am]
BILLING CODE 4410-09-P